AstraZeneca: Oddo welcomes FDA's decision on Imfinzi
(CercleFinance.com) - Oddo BHF has confirmed its "buy" rating on the AstraZeneca share, raising its target price from 5580 pence to 5620 pence, the day after FDA approved Imfinzi for non-small stage III lung cancer.
The analyst pointed out that this is the only immunotherapy that is allowed for patients suffering from this disease, which would represent a market worth between four billion and five billion dollars.
According to the broker's analysts, the pharmaceutical company therefore has a unique competitive advantage in non-small cell lung cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The analyst pointed out that this is the only immunotherapy that is allowed for patients suffering from this disease, which would represent a market worth between four billion and five billion dollars.
According to the broker's analysts, the pharmaceutical company therefore has a unique competitive advantage in non-small cell lung cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.